Life Sciences & Biotechnology, Medical Sciences
Title: | Candidate Drug 80/5Technology Demonstration4 (Anti-dyslipidemic) |
Area: | Life Sciences & Biotechnology, Medical Sciences |
Focus Area: | Hyperlipidemia Treatment |
Patent: | EP1020191, IN193304, US65Technology Demonstration9862, US68Technology Demonstration5Technology Demonstration58 |
Social Benefits: | The compound inhibits the biosynthesis of cholesterol and reduces the rate of cholesterol turnover. It also stimulates the LDL receptor binding activity and thereby increasing the catabolism of LDL cholesterol and significantly reduces the lipid peroxidation. It has a Triglyceride lowering activity als which is the main Lipid abnormality found in Indian population. |
Developing Agency: | CSIR-Central Drug Research Institute (CDRI), Uttar Pradesh |
Technology Readiness Index: | Technology Demonstration |
Email: | director@cdri.res.in |
| Website Link : | http://www.cdri.res.in |
| Source (more info) : | https://t.ly/l_sb |
Brief Description
Description : | Anti-Dyslipidemic drug especially used in Dyslipidemia of Diabetes, Metabolic syndrome Obesity
For managing patients of hyperlipidemia especially triglycerides and cholesterol |
Related Technologies